A

Metabolic Surgery Research

Gut-brain circuitry explains why surgery is metabolic therapy

Tyler M. Cook; Maigen M. Bethea; Darleen A. Sandoval | Current Opinion in Neurobiology, 2025 | PMID 40349608

Cook, Bethea, and Sandoval review how Roux-en-Y gastric bypass and sleeve gastrectomy alter gut-to-brain signaling well beyond stomach size or malabsorption. Weight loss is driven largely by sustained changes in feeding behavior: lower intake, smaller and more frequent meals, shifts in macronutrient preference, reduced hedonic hunger, and altered nutrient-induced brain activation. Candidate signals include vagal and spinal afferents, PYY, GLP-1, CCK, ghrelin, bile acids, FXR/FGF15/19, nutrient sensing, and microbiome changes.

The clinical value is the framing. MBS is not a restrictive workaround for failed willpower but a metabolic intervention that changes appetite, reward, satiety, nutrient flow, gut hormone release, and brain responses to food. No single pathway explains the effect, and surgery works through mechanisms that overlap with but differ from incretin medications.

Reproductive health improves after MBS in a prospective UK cohort

Martin Whyte; Stephanie Attersley-Smith; Kathryn Hart; Sophia Stone; Christopher Pring; Jill Shawe | Obesity Surgery, 2026 | PMID 42554792

Whyte and colleagues followed women aged 18 to 45 undergoing Roux-en-Y gastric bypass or sleeve gastrectomy at a UK center, against a nonsurgical control group. Among 84 surgical participants, 49 underwent bypass and 35 sleeve, with follow-up to 24 months. Mean excess weight loss reached 64% to 73%, sex hormone-binding globulin rose, and free androgen index fell. Reports of irregular menstruation and hirsutism fell, polycystic ovarian morphology was less common, and 20 pregnancies occurred.

Reproductive counseling belongs inside the bariatric pathway, not as an afterthought. Nearly one-third of participants intended pregnancy at baseline, and many pregnancies occurred 12 to 24 months after surgery. Programs should address contraception, pregnancy timing, micronutrition, and obstetric coordination before weight loss accelerates.

Magnetic small-bowel anastomosis moves into pivotal human evidence

Andre Teixeira et al. | Surgical Endoscopy, 2026 | DOI source

The FLOWS North American pivotal trial evaluated the Flexagon self-forming magnet system with OTOLoc for small-bowel anastomosis. Crossref identifies a prospective device study in Surgical Endoscopy, with GI Windows funding and several consultant disclosures. The central claim is immediately functional magnetic compression anastomosis rather than a delayed, fully occlusive connection. Full-text extraction was unavailable in production, so this entry relies on DOI metadata and trial context rather than the abstract.

The interest is obvious but should stay disciplined. Anastomotic technology affects leak risk, bleeding, stricture, operative flow, training, and cost. A magnetic platform could matter for small-bowel bypass and revisional work if it proves reliable in real operations. Watch technical success, adverse events, and conflicts before calling it practice changing.

AI in bariatric surgery needs validation before workflow adoption

Manuel Andrey Felix Castro; Martha Patricia Sánchez Muñoz; Carlos Manuel Moreno Mendoza; Gabriela Zamudio Martínez | Obesity Surgery, 2025 | DOI source

This Obesity Surgery article reviews potential applications of artificial intelligence in bariatric surgery, including education, monitoring, risk prediction, and outcomes work. It is a short article rather than an outcomes trial, and the DOI metadata does not support treating it as clinical evidence. The message is cautious: AI may help organize information and extend monitoring, but it cannot substitute for validated surgical judgment.

Surgeons should read AI papers through an implementation lens. A tool that summarizes notes or flags risk still needs bias checks, local validation, privacy review, and a defined human override. Ask what decision it changes, what harm it could miss, and who is accountable when it fails. Used casually, AI adds confidence without competence.

B

Science of Obesity Metabolism

CKM syndrome severity may identify higher pancreatic cancer risk

Munseok Choi; Seok-Jae Heo; Yu-Jin Kwon; Chang Moo Kang | Diabetes/Metabolism Research and Reviews, 2026 | DOI source

Choi and colleagues used the UK Biobank to examine cardiovascular-kidney-metabolic syndrome stage and incident pancreatic cancer. The cohort included 326,148 participants without pancreatic cancer at baseline, followed a mean of 13.5 years. Incidence rose from 9.0 to 48.6 cases per 100,000 person-years across CKM stages, and adjusted subdistribution hazard ratios roughly doubled for stages 1, 2, and 3 to 4 versus stage 0.

This is not a bariatric paper, but it broadens how surgeons think about metabolic disease severity. CKM staging captures adiposity, diabetes risk, kidney dysfunction, and cardiovascular disease in one frame. If that burden tracks with pancreatic cancer risk, durable obesity treatment becomes part of cancer-prevention thinking, even without proven causality.

Ultra-processed food may act through a gut-brain-adipose loop

Jimmy Chun Yu Louie | Current Obesity Reports, 2026 | DOI source

Louie synthesizes mechanistic literature linking ultra-processed foods to obesity through gut microbial disruption, intestinal barrier changes, hypothalamic inflammation, and adipose-tissue dysfunction. These mechanisms may work as a connected loop rather than separate pathways. The review notes that Nova Group 4 is biologically heterogeneous, placing products with very different physiologic effects in one category. Open access under CC BY; summarized here, not republished.

The review moves ultra-processed food counseling beyond calorie density. Patients often hear that processing is a moral failing; this paper frames it as exposure to food attributes that may alter satiety, inflammation, and reward physiology. Use it to discuss food environment, relapse risk, and why postoperative nutrition should emphasize minimally processed protein and fiber.

Metabolic syndrome-associated osteoarthritis adds risk after revision knee arthroplasty

Miaolan Yuan; Hao Xie; Yanjie He; Yinyin Qin; Jian Wang | Frontiers in Endocrinology, 2026 | PMC full text

This open-access study used Nationwide Inpatient Sample data from 2010 through 2019 to evaluate revision total knee arthroplasty in metabolic syndrome-associated osteoarthritis. Across 1,330,099 revision hospitalizations, MetS-OA was present in 16.1% and rose over time. Those patients had slightly longer stays and higher charges, with no mortality difference, but higher odds of myocardial infarction, renal failure, respiratory distress, delirium, urinary tract infection, and neurologic injury.

The relevance is indirect but real. Metabolic disease changes surgical risk across specialties, and joint disease often sits in the same pathway as severe obesity. Patients seeking MBS may also be trying to qualify for arthroplasty. The paper supports integrated optimization among bariatric, orthopedic, anesthesia, and primary care teams.

Primary care feels underprepared when GLP-1 coverage disappears

Lauren Oshman; Amy Runyon; Alexis Vicenzi Bal; Patricia Arizaca-Dileo; Ananda Sen et al. | Obesity Pillars, 2026 | DOI source

Oshman and colleagues surveyed primary care physicians at an academic Midwestern center after patients lost insurance coverage for GLP-1 weight-management drugs. The response rate was 51%, with 111 of 216 clinicians responding. About half felt uncomfortable helping patients maintain weight after coverage ended, three-quarters expected fewer than a quarter of affected patients to maintain weight loss, and referral to ABOM-certified physicians was the preferred strategy.

The study is small and single-center, but the access problem is national. Discontinuation does not end obesity care; it exposes whether a system has a plan beyond the prescription. Expect more patients who tried GLP-1 therapy, lost coverage, and regained weight. Programs that coordinate medical and surgical obesity care will be better positioned.

C

Metabolic Innovation and Technology

Intuitive frames surgical AI as surgeon-controlled assistance

Sean Whooley | MassDevice, 2026 | Source ↗

MassDevice reports that Intuitive used the Society of Robotic Surgery 2026 meeting to describe its AI roadmap for surgical robotics and telesurgery. The company frames AI as a layered stack built from real-world da Vinci data: data quality, insights, intraoperative guidance, augmented dexterity, and supervised autonomy. Intuitive says its models draw on more than 20 million procedures and aim to reduce variability while preserving surgeon control.

The story is less about immediate practice change than direction of travel. AI-enabled robotics may influence training, coaching, telecollaboration, and intraoperative decision support. But roadmap language is not outcomes evidence. Ask what task the system improves, how it was validated, and whether accountability stays with the operating surgeon.

Social media still fills the GLP-1 education gap

Julia Ivanova, PhD, MA | Telehealth.org, 2026 | Source ↗

This Telehealth.org article reports that many patients using GLP-1 therapies still rely on social media influencers and online communities for practical advice, with questions around dosing, side effects, nutrition, shortages, and compounded products. It is a trade-media synthesis, not a clinical trial, and it discloses AI-assisted research with editorial review, which makes independent clinical verification important.

The practical message is simple: ask patients where they are getting information. They may not volunteer that they follow influencer dosing advice, use supplements marketed as GLP-1 alternatives, or consider gray-market products. Offer reliable handouts, nurse triage, and portal messaging, or social platforms will answer first.

CMS physician-fee comment window deserves MBS attention

Centers for Medicare & Medicaid Services / Regulations.gov | Regulations.gov, 2026 | Comment page

The selected Regulations.gov page opens a comment portal for the CMS proposed rule on the Calendar Year 2027 Physician Fee Schedule and related Part B payment and coverage policies. It offers no bariatric-specific analysis, and no comment should be submitted from this newsletter workflow. The item matters because payment policy, Part B coverage changes, and shared-savings rules shape access and practice economics.

Surgeons and societies should treat comment periods as clinical advocacy, not administrative noise. Reimbursement policy determines whether programs can support multidisciplinary care, revisional work, nutrition services, and longitudinal management. Comments need not read like legal briefs; concrete practice examples carry weight.

Momentis clearance expands flexible robotics across access routes

Sean Whooley | MassDevice, 2026 | Source ↗

MassDevice reports FDA 510(k) clearance for Momentis Surgical’s multiport Anovo configuration, adding conventional multiport use to a platform already supporting natural-orifice and single-port approaches. The system uses internally articulated flexible instruments intended to reduce external arm movement while preserving dexterity. Coverage rests heavily on company claims, so outcome conclusions should wait for comparative data.

The platform is worth watching because abdominal robotics is moving beyond a single access paradigm. A compact flexible robot could matter for ergonomics, space constraints, or case selection. But bariatric value requires proof in bariatric operations: stapling, retraction, hiatal work, leaks, operative time, and cost.

D

Metabolic Marketplace

Medicare GLP-1 Bridge tests limited obesity-drug coverage

Ali Swenson | Associated Press, 2026 | Source ↗

The Associated Press reports that CMS has opened the Medicare GLP-1 Bridge, a temporary program offering selected weight-loss medications to qualifying beneficiaries for $50 per month. It covers Lilly’s Foundayo tablets and Zepbound KwikPens and Novo Nordisk’s Wegovy injections and tablets, with eligibility tied to BMI and comorbidities, and runs through the end of 2027 while CMS collects data.

This is an access experiment with direct referral implications. Some older patients gain coverage for the first time; others remain excluded by diagnosis or BMI threshold. The bridge may delay some referrals and prompt others after medication failure, raising questions about sequencing, frailty, sarcopenia, and nutritional risk in older adults.

Retatrutide expanded access raises pipeline expectations before approval

Sneha S K and Deena Beasley | Reuters, 2026 | Source ↗

Reuters reports that Eli Lilly will allow a limited number of patients early access to retatrutide before FDA approval through an expanded-access pathway. Patients must meet specific criteria, be unable to enroll in a trial, and have refractory obesity despite the highest approved dose of current therapy. Retatrutide targets GLP-1, GIP, and glucagon; Lilly reported 22.6% average weight loss at the top weekly dose over 80 weeks. Filing is planned for the first quarter of 2027.

This does not make retatrutide broadly available, but it changes the conversation around treatment-refractory obesity. Patients will ask about a drug that is not yet approved and reachable only under narrow criteria. Counseling should separate trial efficacy, expanded access, approval, and coverage, and stress that surgery and medication can be sequenced.

Lilly’s GLP-1 sales surge keeps obesity markets centered on injectables

Mrinalika Roy and Mariam E Sunny | Reuters, 2026 | Source ↗

Reuters reports that Eli Lilly beat quarterly expectations and raised full-year revenue guidance on sustained GLP-1 demand. Mounjaro sales rose 91% to $9.94 billion and Zepbound generated $4.93 billion, together 64.7% of quarterly revenue. Lilly raised its outlook to $85 billion to $87 billion, while lower realized prices partly offset volume growth.

Injectable GLP-1 demand remains durable even as oral competitors arrive and pricing pressure grows. Programs should not assume demand is fading, nor that drug growth solves access or durability. High revenue coexists with discontinuation, contraindications, and inadequate response. The question is how to integrate pharmacotherapy without losing the surgical option.